Radiolabeling and biological evaluation of I-125-Necitumumab for EGFR-targeted SPECT imaging

doi:10.1007/s10967-019-06933-8

CORC > 上海应用物理研究所 > 中国科学院上海应用物理研究所 > 中科院上海应用物理研究所2011-2017年

	Radiolabeling and biological evaluation of I-125-Necitumumab for EGFR-targeted SPECT imaging
	Lu, XM ; Li, X ; Peng, Y ; Wang, T ; Li, DN ; Jia, LN ; Zhang, L
刊名	JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY
	2020
卷号	323 期号:1 页码:83-89
关键词	NECITUMUMAB CANCER EXPRESSION CETUXIMAB ANTIBODY IMPACT TUMOR
ISSN号	0236-5731
DOI	10.1007/s10967-019-06933-8
文献子类	期刊论文
英文摘要	Radiolabeled epidermal growth factor receptor (EGFR) targeted antibody could be used for imaging EGFR expressing cancer. In this study, the SPECT probe I-125-Necitumumab were synthesized and evaluated for SPECT imaging of non-small cell lung cancer (NSCLC). In vivo biodistribution study indicated that I-125-Necitumumab was cleared rapidly in most organs and tissues. Though the tumor expressed a relatively high level of EGFR, however SPECT images showed no obvious uptake in the tumors. Therefore, we considered that I-125-Necitumumab was not suitable for EGFR-targeted NSCLC SPECT imaging.
语种	英语
内容类型	期刊论文
源URL	[http://ir.sinap.ac.cn/handle/331007/33100]
专题	上海应用物理研究所_中科院上海应用物理研究所2011-2017年
作者单位	1.Chinese Acad Sci, Shanghai Inst Appl Phys SINAP, Shanghai 201800, Peoples R China 2.Univ Chinese Acad Sci, Beijing 100049, Peoples R China 3.Changhai Hosp, Dept Nucl Med, Shanghai 200433, Peoples R China
推荐引用方式 GB/T 7714	Lu, XM,Li, X,Peng, Y,et al. Radiolabeling and biological evaluation of I-125-Necitumumab for EGFR-targeted SPECT imaging[J]. JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY,2020,323(1):83-89.
APA	Lu, XM.,Li, X.,Peng, Y.,Wang, T.,Li, DN.,...&Zhang, L.(2020).Radiolabeling and biological evaluation of I-125-Necitumumab for EGFR-targeted SPECT imaging.JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY,323(1),83-89.
MLA	Lu, XM,et al."Radiolabeling and biological evaluation of I-125-Necitumumab for EGFR-targeted SPECT imaging".JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY 323.1(2020):83-89.